METHOD OF PREVENTING THROMBOTIC COMPLICATIONS OF PREGNANCY IN WOMEN WITH NON-DIFFERENTIATED FORMS OF MESENCHYMAL DYSPLASIA Russian patent published in 2014 - IPC G01N33/48 

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to obstetrics and gynecology, and can be used for prevention of thrombotic complications of pregnancy in women with non-differentiated forms of mesenchymal dysplasia. For this purpose level of soluble fibrin-monomer complexes (SFMC) is measured, and depending on their quantity heparin therapy is performed in I trimester of pregnancy transdermally if SFMC level in blood plasma is higher than 7.5 mg/100 ml. Injection heparin therapy is performed under skin of anterior abdominal wall with nadroparin calcium if SFMC level is higher than 16.00 mg/100 ml. In II trimester of pregnancy heparin therapy is performed transdermally if SFMC level in blood plasma is higher than 8.0 mg/100 ml, perorally - if SFMC value is higher than 11.5 mg/100 ml, injection heparin therapy under skin - if level is 16.00 mg/100 ml and higher. In III trimester of pregnancy therapy is performed transdermally if SFMC level in blood plasma is higher than 8.5 mg/100 ml, perorally if SFMC level is higher than 12.0 mg/100 ml. Injection heparin therapy is performed under skin if level is 16.00 mg/100 ml and higher than said level. Additionally in II and III trimesters angioprotector is administered: dipyridamole 50 mg 3 times per day for 30 days and hepatoprotector: essential phospholipids 300 mg 3 times per day for 60 days. In all trimesters vitamin-mineral complex is introduced taking into account individual indices of magnesium, calcium and zinc level in blood plasma.

EFFECT: invention ensures reduction of frequency of complications of pregnancy and, therefore, number of hospitalisations, as well as reproductive losses.

3 ex